RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review

March 2021 | 56 pages | ID: R0AD238207FEN
GlobalData

Abstracts

RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC, is a clinical-stage biotechnology company. It discovers and develops gene therapy for the treatment of various retinal, metabolic, and neurodegenerative diseases. The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy. Its products include AAV plasmids, AAV vector reporter systems and custom AAV vectors. The company’s gene therapy product candidates deliver genes to cells for addressing genetic defects and enable cells in the body to produce therapeutic proteins or antibodies that act on the disease. RegenxBio employs its proprietary NAV technology platform, a gene delivery technology, to advance its product candidates. RegenxBio is headquartered in Rockville, Maryland, the US.

RegenxBio Inc Key Recent Developments

Feb 05,2021: REGENXBIO announces presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference
Feb 01,2021: REGENXBIO announces presentations at the 17th annual WORLDSymposium 2021
Nov 04,2020: REGENXBIO reports third quarter 2020 financial results and operational highlights
Aug 06,2020: REGENXBIO reports second quarter 2020 financial results and operational highlights
Jun 29,2020: Regenxbio announces the resignation from the Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

RegenxBio Inc - Key Facts
RegenxBio Inc - Key Employees
RegenxBio Inc - Key Employee Biographies
RegenxBio Inc - Major Products and Services
RegenxBio Inc - History
RegenxBio Inc - Company Statement
RegenxBio Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
RegenxBio Inc - Business Description
R&D Overview
RegenxBio Inc - Corporate Strategy
RegenxBio Inc - SWOT Analysis
SWOT Analysis - Overview
RegenxBio Inc - Strengths
RegenxBio Inc - Weaknesses
RegenxBio Inc - Opportunities
RegenxBio Inc - Threats
RegenxBio Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
RegenxBio Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 05, 2021: REGENXBIO announces presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference
Feb 01, 2021: REGENXBIO announces presentations at the 17th annual WORLDSymposium 2021
Nov 04, 2020: REGENXBIO reports third quarter 2020 financial results and operational highlights
Aug 06, 2020: REGENXBIO reports second quarter 2020 financial results and operational highlights
Jun 29, 2020: Regenxbio announces the resignation from the Board of Directors
May 01, 2020: REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights
Apr 01, 2020: REGENXBIO and Ultragenyx announce new license agreement for use of NAV technology platform for the treatment of Rare Metabolic Disorder
Feb 26, 2020: REGENXBIO reports fourth quarter and full-year 2019 financial results and operational highlights
Jan 09, 2020: REGENXBIO reports continued progress across programs in year-end 2019 corporate update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

RegenxBio Inc, Key Facts
RegenxBio Inc, Key Employees
RegenxBio Inc, Key Employee Biographies
RegenxBio Inc, Major Products and Services
RegenxBio Inc, History
RegenxBio Inc, Subsidiaries
RegenxBio Inc, Key Competitors
RegenxBio Inc, Ratios based on current share price
RegenxBio Inc, Annual Ratios
RegenxBio Inc, Annual Ratios (Cont...1)
RegenxBio Inc, Annual Ratios (Cont...2)
RegenxBio Inc, Interim Ratios
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
RegenxBio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

RegenxBio Inc, Performance Chart (2016 - 2020)
RegenxBio Inc, Ratio Charts
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021